MedSuite

Systemic Sclerosis (Scleroderma)

Rheumatology / Autoimmune

Overview

Definition

A rare autoimmune disease characterized by progressive fibrosis of the skin and internal organs.

Epidemiology

More common in women (peak onset 30-50 years).

Etiology & Risk Factors

  • Autoimmune endothelial damage leading to excessive collagen deposition (fibrosis) by fibroblasts.

Clinical Symptoms

  • Limited Cutaneous (CREST syndrome): Calcinosis cutis, Raynaud's phenomenon, Esophageal dysmotility, Sclerodactyly (tight skin on fingers), Telangiectasias
  • Diffuse Cutaneous: Widespread skin fibrosis (chest, abdomen) and early, severe visceral organ involvement
  • Raynaud's phenomenon (cold-induced vasospasm causing fingers to turn white, then blue, then red) is almost universal and often the first symptom.

Clinical Approach

Diagnosis

  • Clinical findings
  • Antibodies: Anti-Centromere antibodies (associated with Limited/CREST), Anti-Scl-70 (anti-topoisomerase I, associated with Diffuse/severe disease and pulmonary fibrosis)

Management

  • Raynaud's: Calcium Channel Blockers (Nifedipine) to vasodilate
  • Esophageal Reflux: PPIs
  • Scleroderma Renal Crisis (life-threatening hypertension): ACE Inhibitors are life-saving
  • Pulmonary Fibrosis / Interstitial Lung Disease: Immunosuppressants (Cyclophosphamide, Mycophenolate)

Complications

  • Pulmonary Arterial Hypertension (leading cause of death in Limited disease)
  • Interstitial Lung Disease (leading cause of death in Diffuse disease)
  • Scleroderma Renal Crisis